Survival after HCT for advanced AML based on 5 risk factors: first CR duration <6 months, circulating blasts, non-HLA-identical sibling donor, performance score <90%, and poor-risk cytogenetics. CI, confidence interval. Adapted with permission from Duval et al.³³